Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1137-1145

  Ruiz Palacios, Guillermo M ^a   Guerrero, M Lourdes ^a   Hernández Delgado, Lorena ^b   Lavalle Villalobos, Antonio ^b   Casas Muñoz, Abigail ^a   Cervantes Apolinar, Yolanda ^c   Moreira, Marta ^d   Schuerman, Lode ^d  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c GLAXOSMITHKLINE   (Mexico)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunogenicity; Nontypeable Haemophilus influenzae; Pneumococcal vaccine; Safety; Streptococcus pneumoniae

Indexed keywords

BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHOPNEUMONIA; CONTROLLED STUDY; CONVULSION; CROSS REACTION; DIARRHEA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INCIDENCE; INFANT; INFLUENZA VACCINATION; INJECTION SITE BLEEDING; INJECTION SITE PAIN; IRRITABILITY; MALE; MEXICO; MULTICENTER STUDY; PAIN ASSESSMENT; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; RHINOPHARYNGITIS; SEROTYPE; SIDE EFFECT; SKIN REDNESS; SKIN SWELLING; VOMITING;

EID: 81855227708     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17984     Document Type: Article

References (50)

1. World Health Organization (WHO). Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007; 82:93-104; PMID:17380597.
2. Camargos P, Fischer GB, Mocelin H, Dias C, Ruvinsky R. Penicillin resistance and serotyping of Streptococcus pneumoniae in Latin America. Paediatr Respir Rev 2006; 7:209-14; PMID:16938644; DOI:10.1016/j. prrv.2006.04.004.
3. di Fabio JL, Homma A, de Quadros C. Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. Microb Drug Resist 1997; 3:131-3; PMID:9185139; DOI:10.1089/ mdr.1997.3.131.
4. Castañeda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, Brandão AP, et al. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 2009; 28:265-70; PMID:19710581; DOI:10.1097/ INF.0b013e3181a74b22.
5. Garcia S, Levine OS, Cherian T, Gabastou JM, Andrus J. Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction. Rev Panam Salud Publica 2006; 19:340-8; PMID:16805976; DOI:10.1590/S1020- 49892006000500007.
6. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187- 95; PMID:10749457; DOI:10.1097/00006454- 200003000-00003.
7. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9; PMID:11172176; DOI:10.1056/ NEJM200102083440602.
8. Akkoyunlu M, Ruan M, Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun 1991; 59:1231-8; PMID:1900807.
9. Janson H, Ruan M, Forsgren A. Limited diversity of the protein D gene (hpd) among encapsulated and nonencapsulated Haemophilus influenzae strains. Infect Immun 1993; 61:4546-52; PMID:8104899.
10. Munson RS Jr, Sasaki K. Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase. J Bacteriol 1993; 175:4569-71; PMID:8392514.
11. Song XM, Forsgren A, Janson H. The gene encoding protein D (hpd) is highly conserved among Haemophilus influenzae type b and nontypeable strains. Infect Immun 1995; 63:696-9; PMID:7822043.
12. Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 1999; 67:2746-62; PMID:10338477.
13. Janson H, Melhus A, Hermansson A, Forsgren A. Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model. Infect Immun 1994; 62:4848-54; PMID:7927765.
14. Janson H, Carl n B, Cervin A, Forsgren A, Magnusdottir AB, Lindberg S, et al. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis 1999; 180:737-46; PMID:10438362; DOI:10.1086/314921.
15. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 2004; 72:5383-91; PMID:15322036; DOI:10.1128/ IAI.72.9.5383-91.2004.
16. 197 conjugates. Expert Rev Vaccines 2008; 7:97-115; PMID:18251697; DOI:10.1586/14760584.7.1.97.
17. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; DOI:10.1016/S0140- 6736(06)68304-9.
18. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009; 28:89-96; PMID:19325451; DOI:10.1097/ INF.0b013e318199f901.
19. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 2009; 28:109-18; PMID:19325447; DOI:10.1097/INF.0b013e318199f62d.
20. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28:97-108; PMID:19325452; DOI:10.1097/INF.0b013e318199f61b.
21. Lagos RE, Muñoz A, Levine M, Lepetic A, François N, Yarzabal J, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 2011; 7:511-22; PMID:21441782; DOI:10.4161/hv.7.5.14634.
22. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:66-76; PMID:19325449; DOI:10.1097/ INF.0b013e318199f8ef.
23. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia- Sicilia J, Knuf M, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009; 28:77-88; PMID:19325450; DOI:10.1097/ INF.0b013e318199f609.
24. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339-50; PMID:19837254; DOI:10.1016/ S0140-6736(09)61208-3.
25. Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J 2009; 28:276-82; PMID:20118683; DOI:10.1097/ INF.0b013e3181b48ca3.
26. Bermal N, Szenborn L, Alberto E, Hernandez M, Pejcz J, Majda-Stanislawska E, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/ Hib and poliovirus vaccines. Pediatr Infect Dis J 2011; 30:69-72; PMID:20980933; DOI:10.1097/ INF.0b013e3181f2da06.
27. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubellavaricella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J 2010; 29:47-56; PMID:20508478; DOI:10.1097/INF. 0b013e3181dffabf.
28. Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine MM, et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanuspertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 1998; 16:921-7; PMID:9682338; DOI:10.1016/S0264-410X(97)00303-4.
29. Lagos R, Hoffenbach A, Scemama M, Dupuy M, Schodel F, Hessel L, et al. Lot-to-lot consistency of a combined hexavalent diphtheria-tetanus-acellular- pertussis, hepatitis B, inactivated polio and Haemophilus B conjugate vaccine, administered to healthy Chilean infants at two, four and six months of age. Hum Vaccin 2005; 1:112-7; PMID:17012870; DOI:10.4161/ hv.1.3.1848.
30. Puumalainen T, Dagan R, Wuorimaa T, Zeta-Capeding R, Lucero M, Ollgren J, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003; 22:141-9; PMID:12586978; DOI:10.1097/01. inf.0000050459.74134.d5.
31. Väkeväinen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010; 157:778-83; PMID:20547399; DOI:10.1016/j.jpeds.2010.04.071.
32. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1,666 children. Clin Infect Dis 2003; 37:1155-64; PMID:14557958; DOI:10.1086/378744.
33. Lucero MG, Nohynek H, Williams G, Tallo V, Simões EA, Lupisan S, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, doubleblind, placebo-controlled trial. Pediatr Infect Dis J 2009; 28:455-62; PMID:19483514; DOI:10.1097/ INF.0b013e31819637af.
34. 197-conjugated pneumococcal- meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine 2008; 26:4178-86; PMID:18606481; DOI:10.1016/j.vaccine.2008.05.072.
35. Wuorimaa TK, Dagan R, Bailleux F, Haikala R, Ekström N, Eskola J, et al. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine 2005; 23:5328-32; PMID:16118028; DOI:10.1016/j.vaccine.2005.06.023.
36. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502; PMID:17071283; DOI:10.1016/S0140-6736(06)69637-2.
37. Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011; 18:327-36; PMID:21123523; DOI:10.1128/CVI.00402-10.
38. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010; 10:4; PMID:20122261; DOI:10.1186/1471-2431-10-4.
39. Bakaletz LO. Peptide and recombinant antigens for protection against bacterial middle ear infection. Vaccine 2001; 19:2323-8; PMID:11257356; DOI:10.1016/ S0264-410X(00)00522-3.
40. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008; 46:726-31; PMID:18230042; DOI:10.1086/527396.
41. Bakaletz LO. Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention. Expert Rev Vaccines 2009; 8:1063-82; PMID:19627188; DOI:10.1586/erv.09.63.
42. Novotny LA, Jurcisek JA, Godfroid F, Poolman JT, Denoel PA, Bakaletz LO. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine 2006; 24:4804-11; PMID:16616975; DOI:10.1016/j.vaccine. 2006.03.021.
43. Manjarrez ME, Rosete DP, Rincon M, Villalba J, Cravioto A, Cabrera R. Comparative viral frequency in Mexican children under 5 years of age with and without upper respiratory symptoms. J Med Microbiol 2003; 52:579-83; PMID:12808080; DOI:10.1099/ jmm.0.05007-0.
44. Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 2009; 27:7257-69; PMID:19833248; DOI:10.1016/j.vaccine. 2009.09.111.
45. Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266- 72; PMID:11238206.
46. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356- 60; PMID:16522777; DOI:10.1128/CVI.13.3.356- 60.2006.
47. Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-72; PMID:12804857; DOI:10.1016/S0264-410X(03)00230-5.
48. World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. 2005. Report No. 927, Annex 2.
49. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-22; PMID:9220157.
50. Henckaerts I, Durant N, De GD, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007; 25:2518-27; PMID:17034907; DOI:10.1016/j.vaccine. 2006.09.029.